Robert Dolski - 27 Jan 2022 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Role
Chief Financial Officer
Signature
/s/ Kleem Chaudhary, attorney-in-fact
Issuer symbol
N/A
Transactions as of
27 Jan 2022
Net transactions value
$0
Form type
4
Filing time
31 Jan 2022, 15:05:37 UTC
Previous filing
06 Aug 2021
Next filing
31 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMPI Stock Option (Right to Buy) Award $0 +101,180 $0.000000 101,180 27 Jan 2022 Common Stock 101,180 $2.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to such option vest and become exercisable on January 27, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.